DHL Global Forwarding has switched on six dedicated air freight corridors linking its European and North American hubs with pharmaceutical markets in Asia, the latest build-out of its temperature-controlled healthcare network.

The routes connect Liège with Shanghai, Brussels with Shanghai and Singapore, and Cincinnati with Singapore, Tokyo Narita and Seoul Incheon. That's three gateways on the western side, four Asian endpoints on the other. Together they stitch together the manufacturing, research and distribution centres where most of the world's medicines, vaccines, biologics and clinical trial materials actually move.

Why dedicated corridors matter for pharma shippers

What does this change for a pharmaceutical shipper? In short: routing options and fewer hands on the box.

DHL says most of the flights run on its own aircraft, which cuts the number of operator handovers during a journey. Every handover is a risk point for temperature excursions — the moments when a pallet of biologics sits on an apron or gets reloaded into a hold set to the wrong temperature. Fewer transfers mean tighter control over what DHL calls critical quality parameters.

The hardware matters too. DHL operates Boeing 777 freighters fitted with three compartments offering different temperature settings, so a single aircraft can carry shipments with distinct thermal requirements. On the ground, the network relies on thermal blankets and validated handling procedures to keep cargo inside its required temperature range during transfers.

Control, not just capacity

The commercial logic here is straightforward. Pharma freight is high-value, low-tolerance cargo, and shippers pay a premium for reliability rather than speed alone. By flying its own metal on the majority of these corridors, DHL captures margin it would otherwise share with third-party carriers, and it can guarantee the handling chain end to end.

Henk Venema, global head of air freight at DHL Global Forwarding, said: "These new corridors further expand our Cold Chain Network into strategically important healthcare markets across Asia. They respond to customer demand for reliable connectivity between major healthcare markets while giving us greater control over critical quality parameters throughout the transportation process."

That second half of the quote is the tell. Reliability is what customers asked for; control is what DHL gets. Both point the same direction — vertically integrated cold chain provision, not spot capacity.

Building on an existing pattern

The six corridors don't arrive in a vacuum. DHL launched a Brussels–Cincinnati corridor earlier this year, and the new routes extend that architecture across the Pacific and deeper into Asia.

There's an infrastructure leg to the strategy as well. DHL has been investing in healthcare logistics capacity in Singapore, with a new cold chain hub planned at Changi Nexus One, inside Changi Airport's Free Trade Zone. A hub at Changi plus a corridor from Cincinnati to Singapore gives DHL an anchor on both ends of the transpacific pharma flow — and positions it against the freighter networks and airport pharmaceutical communities that have been chasing the same cargo.

For forwarders competing in life sciences logistics, the signal is that integrated carriers are consolidating the premium end of the market. Temperature-controlled capacity on scheduled, dedicated corridors is harder to replicate than a booking on a passenger belly.

What comes next

The pattern so far suggests more of the same: corridor-by-corridor expansion anchored by owned freighter capacity and hub infrastructure. With pharma volumes growing on the Asia–Europe and transpacific lanes and cold chain compliance requirements tightening, DHL's bet is that dedicated thermal capacity — on its own 777s, through its own hubs — will keep pulling healthcare freight away from general cargo networks.